• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱切除术病理报告实践的变化——来自对 212 名病理学家的国际调查结果。

Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists.

机构信息

School of Medicine and Population Health, University of Sheffield, Sheffield, UK.

Histopathology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

出版信息

Virchows Arch. 2024 Nov;485(5):879-888. doi: 10.1007/s00428-024-03924-3. Epub 2024 Sep 7.

DOI:10.1007/s00428-024-03924-3
PMID:39243298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11564217/
Abstract

The pathological assessment of cystectomy specimens is important for accurate prognostic information and to inform adjuvant therapy decisions. However, there is limited evidence regarding the best approach to fixation, dissection, block selection and microscopic assessment of cystectomies. We report the results of an international survey of 212 pathologists and their approach to cystectomy pathology. There is variation at all stages of the specimen journey including in fixation and dissection techniques, and in the approach to evaluating residual tumour. This is particularly evident in the post-neoadjuvant chemotherapy setting where there is variable use of response scoring systems and differing approaches to sampling. We also find variation in the use of digital and molecular pathology in cystectomy specimens. Finally, we have suggested areas for future research in cystectomy pathological assessment.

摘要

膀胱切除术标本的病理学评估对于准确的预后信息和辅助治疗决策非常重要。然而,关于膀胱切除术的最佳固定、解剖、切块选择和显微镜评估方法的证据有限。我们报告了对 212 名病理学家及其膀胱切除术病理学方法的国际调查结果。在标本处理的所有阶段都存在差异,包括固定和解剖技术,以及评估残留肿瘤的方法。在新辅助化疗后,这种差异尤其明显,因为使用的反应评分系统不同,采样方法也不同。我们还发现膀胱切除术标本中数字病理学和分子病理学的使用存在差异。最后,我们提出了未来在膀胱切除术病理评估方面的研究领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/a954ee107fd3/428_2024_3924_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/799e50b2ab8b/428_2024_3924_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/9adf332faf7c/428_2024_3924_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/705776e8e2ab/428_2024_3924_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/a954ee107fd3/428_2024_3924_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/799e50b2ab8b/428_2024_3924_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/9adf332faf7c/428_2024_3924_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/705776e8e2ab/428_2024_3924_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5093/11564217/a954ee107fd3/428_2024_3924_Fig4_HTML.jpg

相似文献

1
Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists.膀胱切除术病理报告实践的变化——来自对 212 名病理学家的国际调查结果。
Virchows Arch. 2024 Nov;485(5):879-888. doi: 10.1007/s00428-024-03924-3. Epub 2024 Sep 7.
2
Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?新辅助化疗后膀胱切除标本的当前大体检查及报告模式:是否到了采用标准化方法的时候?
Am J Clin Pathol. 2024 May 2;161(5):483-489. doi: 10.1093/ajcp/aqad176.
3
Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.肌层浸润性膀胱癌围手术期化疗的趋势和适宜性。
Urol Oncol. 2019 Jul;37(7):462-469. doi: 10.1016/j.urolonc.2019.04.006. Epub 2019 Apr 30.
4
Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.鉴别肌层浸润性膀胱癌患者新辅助化疗的应用模式和质量。
Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17.
5
The Rate of Neoadjuvant Chemotherapy Use in Muscle Invasive Bladder Cancer and The Approach of Urologists in Turkey.土耳其肌肉浸润性膀胱癌新辅助化疗的使用比例及泌尿科医生的治疗方法。
Urol J. 2016 Oct 10;13(5):2841-2844.
6
Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies.膀胱癌更新的病理学报告标准:活检、经尿道切除术和根治性膀胱切除术。
World J Urol. 2022 Apr;40(4):915-927. doi: 10.1007/s00345-021-03831-1. Epub 2021 Sep 23.
7
Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.新辅助化疗后乳腺癌标本的病理报告实践——对美国学术机构病理学家的调查。
Mod Pathol. 2020 Jan;33(1):91-98. doi: 10.1038/s41379-019-0326-5. Epub 2019 Aug 5.
8
ASCP survey on anatomic pathology examination of the urinary bladder.
Am J Clin Pathol. 1994 Dec;102(6):715-23. doi: 10.1093/ajcp/102.6.715.
9
Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.八旬膀胱癌肌层浸润性癌患者的治疗模式和总生存结局:国家癌症数据库分析。
J Urol. 2018 Feb;199(2):416-423. doi: 10.1016/j.juro.2017.08.086. Epub 2017 Aug 24.
10
Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology.前列腺癌和膀胱癌盆腔淋巴结切除术标本的处理和报告:欧洲泌尿病理学网络的一项基于网络的调查。
Histopathology. 2019 May;74(6):844-852. doi: 10.1111/his.13818. Epub 2019 Apr 1.

引用本文的文献

1
The Handling and Sampling of Radical Cystectomy Specimens: A Standardized Approach for Pathological Evaluation.根治性膀胱切除术标本的处理与取样:病理评估的标准化方法
Methods Protoc. 2025 Apr 5;8(2):35. doi: 10.3390/mps8020035.

本文引用的文献

1
Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms.在线症状调查和临床试验中患者的性别代表性对骨髓增殖性肿瘤的影响。
Leuk Lymphoma. 2024 Oct;65(10):1465-1473. doi: 10.1080/10428194.2024.2356058. Epub 2024 Jun 2.
2
Citizen scientists: Unveiling motivations and characteristics influencing initial and sustained participation in an agricultural project.公民科学家:揭示影响农业项目初始和持续参与的动机和特征。
PLoS One. 2024 May 20;19(5):e0303103. doi: 10.1371/journal.pone.0303103. eCollection 2024.
3
Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
新辅助化疗后膀胱切除标本的当前大体检查及报告模式:是否到了采用标准化方法的时候?
Am J Clin Pathol. 2024 May 2;161(5):483-489. doi: 10.1093/ajcp/aqad176.
4
Macroscopic examination of pathology specimens: a critical reappraisal.病理学标本的宏观检查:批判性再评价。
J Clin Pathol. 2024 Feb 19;77(3):164-168. doi: 10.1136/jcp-2023-209045.
5
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南:2023 年指南摘要。
Eur Urol. 2024 Jan;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016. Epub 2023 Oct 17.
6
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.膀胱癌的定义、终点和临床试验设计:癌症免疫治疗学会和国际膀胱癌协会的建议。
J Clin Oncol. 2023 Dec 10;41(35):5437-5447. doi: 10.1200/JCO.23.00307. Epub 2023 Oct 4.
7
Histopathology reporting of temporal artery biopsy specimens for giant cell arteritis: results of a modified Delphi study.巨细胞动脉炎颞动脉活检标本的组织病理学报告:一项改良 Delphi 研究的结果。
J Clin Pathol. 2024 Jun 19;77(7):464-470. doi: 10.1136/jcp-2023-208810.
8
Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: A 20-year experience.根治性膀胱切除术后无残留疾病(pT0N0)的膀胱癌患者的复发模式:20 年经验。
Urol Oncol. 2023 Feb;41(2):107.e9-107.e14. doi: 10.1016/j.urolonc.2022.09.013. Epub 2022 Nov 22.
9
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.新辅助阿替利珠单抗治疗铂类药物不适合的肌层浸润性膀胱癌患者的最终结果。
Eur Urol. 2022 Aug;82(2):212-222. doi: 10.1016/j.eururo.2022.04.013. Epub 2022 May 14.
10
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.在局部晚期肌层浸润性膀胱癌中,在新辅助吉西他滨和顺铂基础上加用尼达尼布或安慰剂(NEOBLADE):一项双盲、随机、2期试验。
Lancet Oncol. 2022 May;23(5):650-658. doi: 10.1016/S1470-2045(22)00158-9. Epub 2022 Apr 11.